Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) granted an inducement award of 240,500 restricted stock units (RSUs) on June 10, 2026 to 10 newly hired employees.
The RSUs vest in three equal annual installments starting June 10, 2027, under the 2025 Inducement Award Plan and in line with Nasdaq Listing Rule 5635(c)(4).
Positive
- Grant of 240,500 RSUs to support recruitment of 10 new employees
- Three-year RSU vesting schedule designed to encourage employee retention
Negative
- New RSU grants create potential equity dilution for existing shareholders
News Market Reaction – FTRE
On the day this news was published, FTRE gained 3.24%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) on June 10, 2026, to 10 newly hired employees. The award consisted of 240,500 RSUs that vest in three equal annual installments starting June 10, 2027, subject to the employee’s continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company’s Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to the individual becoming a new employee of the Company.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.
Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
